scholarly journals Erratum to: Neointimal coverage and vasodilator response to titanium-nitride-oxide-coated bioactive stents and everolimus-eluting stents in patients with acute coronary syndrome: insights from the BASE-ACS trial

2013 ◽  
Vol 29 (8) ◽  
pp. 1915-1915
Author(s):  
Pasi P. Karjalainen ◽  
Tuomas O. Kiviniemi ◽  
Tuomas Lehtinen ◽  
Wail Nammas ◽  
Antti Ylitalo ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Titanium Nitride ◽  
Coronary Syndrome ◽  
Vasodilator Response ◽  
Neointimal Coverage ◽  
Nitride Oxide

Optical coherence tomography follow-up 18 months after titanium-nitride-oxide-coated versus everolimus-eluting stent implantation in patients with acute coronary syndrome

2016 ◽  
Vol 58 (9) ◽  
pp. 1077-1084
Author(s):  
Pasi Karjalainen ◽  
Tuomas Paana ◽  
Antti Ylitalo ◽  
Jussi Sia ◽  
Wail Nammas
Keyword(s):  
Optical Coherence Tomography ◽  
Acute Coronary Syndrome ◽  
Titanium Nitride ◽  
Cross Sections ◽  
Coronary Syndrome ◽  
Stent Strut ◽  
Neointimal Coverage ◽  
Nitride Oxide ◽  
Level Analysis

Background Inadequate neointimal coverage of stent struts is associated with late stent thrombosis. Purpose To demonstrate the extent of neointimal coverage and strut malapposition in titanium-nitride-oxide-coated bioactive stents (BAS) versus everolimus-eluting stents (EES) by optical coherence tomography (OCT) performed at 18-month follow-up. Material and Methods In the BASE-ACS trial, 827 patients presenting with acute coronary syndrome were randomized to receive either BAS or EES. Forty patients (20 BAS, 20 EES) underwent OCT at 18-month follow-up for evaluation of stent strut coverage, malapposition, and neointimal hyperplasia (NIH). Primary endpoint was binary stent strut coverage (ratio of covered struts to all analyzed struts multiplied by 100). Co-primary endpoint was the percentage of malapposed struts. Results We analyzed 3465 struts in 330 cross-sections of BAS and 3327 struts in 316 cross-sections of EES. Binary stent strut coverage, based on strut-level analysis, was higher with BAS versus EES (99.5% versus 94.2%, respectively; P < 0.001), the strut-level percentage of malapposed struts was lower with BAS (0.6% versus 2.5%, respectively; P < 0.001). Yet, the mean NIH thickness was greater with BAS (237 ± 125 versus 108 ± 62 µm, respectively; P < 0.001). Conclusion In the current post-hoc analysis with OCT performed at 18 months, binary strut coverage, based on strut-level analysis, was higher with BAS versus EES; strut-level malapposed struts were fewer with BAS; yet, BAS induced thicker NIH.

scholarly journals Titanium-Nitride-Oxide–Coated Versus Everolimus-Eluting Stents in Acute Coronary Syndrome

2020 ◽  
Vol 13 (14) ◽  
pp. 1697-1705 ◽  
Author(s):  
Pim A.L. Tonino ◽  
Nico H.J. Pijls ◽  
Carlos Collet ◽  
Wail Nammas ◽  
Jan Van der Heyden ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Titanium Nitride ◽  
Coronary Syndrome ◽  
Nitride Oxide

A prospective randomised comparison of titanium-nitride-oxide-coated bioactive stents with everolimus-eluting stents in acute coronary syndrome: the BASE-ACS trial

2012 ◽  
Vol 8 (3) ◽  
pp. 306-315 ◽  
Author(s):  
Pasi P. Karjalainen ◽  
Matti Niemelä ◽  
Juhani K.E. Airaksinen ◽  
Fernando Rivero-Crespo ◽  
Hannu Romppanen ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Titanium Nitride ◽  
Coronary Syndrome ◽  
Nitride Oxide

scholarly journals Mobilization of progenitor cells and vessel healing after implantation of SYNERGY in acute coronary syndrome

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Masashi Sakuma ◽  
Setsu Nishino ◽  
Takahisa Nasuno ◽  
Michiya Kageyama ◽  
Michiaki Tokura ◽  
...  
Keyword(s):  
Optical Coherence Tomography ◽  
Acute Coronary Syndrome ◽  
Progenitor Cells ◽  
Stent Implantation ◽  
Healing Process ◽  
Coronary Syndrome ◽  
Neointimal Thickness ◽  
Coronary Stent Implantation ◽  
Coronary Angioscopy ◽  
Neointimal Coverage

AbstractThis study was aimed to compare the vascular healing process of a SYNERGY stent with that of a PROMUS PREMIER stent in patients with acute coronary syndrome (ACS). In 71 patients with ACS, undergoing coronary stent implantation using the SYNERGY stent (n = 52) or PROMUS PREMIER stent (n = 19), we measured circulating CD34+/CD133+/CD45null cells and CD34+/KDR+ cells and observed vascular healing at the stented sites using optical coherence tomography (OCT) and coronary angioscopy. On the day 7, circulating CD34+/CD133+/CD45null cells increased in SYNERGY group (P < 0.0001), while it did not change in PROMUS group. The CD34+/KDR+ cells also increased in SYNERGY group (P < 0.0001) but less significantly in the PROMUS group (P < 0.05). The OCT-based neointimal thickness (P < 0.0005) and neointimal coverage rate (P < 0.05) at 12 months were greater in SYNERGY group, compared with PROMUS group. The coronary angioscopy-based neointimal coverage grade at 12 months was also greater in SYNERGY group (P < 0.001). In overall patients, the change in CD34+/KDR+ cells on the day 7 correlated with the OCT-based neointimal thickness at 12 months (R = 0.288, P < 0.05). SYNERGY stent seems to have potential advantages over PROMUS PREMIER stent for ACS patients in terms of vascular healing process at the stented sites.

Comparison of neointimal coverage between biodegradable-polymer everolimus-eluting stent and durable-polymer everolimus-eluting stent using angioscopy for the patients with acute coronary syndrome

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
T Umemoto ◽  
J Matsuda ◽  
Y Hatano ◽  
T Lee ◽  
T Yonetsu ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Biodegradable Polymer ◽  
Cobalt Chromium ◽  
Coronary Syndrome ◽  
Clinical Events ◽  
Yellow Plaque ◽  
Durable Polymer ◽  
Large Populations ◽  
Neointimal Coverage ◽  
Stent Diameter

Abstract Background New-generation biodegradable-polymer platinum chromium everolimus-eluting stent (BP-PtCr-EES) is available, which has different polymer and alloy compare to more established stent design, a durable-polymer cobalt-chromium everolimus-eluting stent (DP-CoCr-EES). Purpose To compare neointimal coverage (NIC) between BP-PtCr-EES and DP-CoCr-EES by using coronary angioscopy (CAS). Methods A total of 36 patients (44 stents) with BP-PtCr-EES or DP-CoCr-EES who underwent CAS at 1 year after stenting were investigated. We compared angioscopic findings assessed by angioscopy between BP-PtCr-EES (n=18) and DP-CoCr-EES (n=26). NIC grade and yellow plaque grade (YPG) was adopted from earlier reports from grade 0 to 3. We determined maximum (max-) and minimum (min-) NIC grade and heterogeneity score (HGS = max NIC grade minus min NIC grade). We also assessed YPG and the presence of thrombus (TH). Results Six lesions (33.3%) in BP-PtCr-EES group and 7 (26.9%) lesions in DP-CoCr-EES group were culprit lesions of acute coronary syndrome, which did not statistically differ between the two groups (p=0.74). And there were no significant differences in stent diameter (BP-PtCr-EES: 2.97±0.39 mm vs DP-CoCr-EES: 3.14±0.45 mm, p=0.22) and length (BP-PtCr-EES: 26.9±7.9 mm vs DP-CoCr-EES: 28.4±8.0 mm, p=0.54). In terms of CAS findings, BP-PtCr-EES group has better neointimal coverage than DP-CoCr-EES group (max NIC grade: 2.6±0.7 vs 2.0±0.9, p=0.01. min NIC grade: 1.1±0.8 vs 0.5±0.5, p&lt;0.01), but HGS was almost same (1.6±0.7 vs 1.5±0.9, p=0.70). YPG of BP-PtCr-EES group showed significantly lower than DP-CoCr-EES group (1.0±1.0 vs 1.7±1.0, p=0.02). The rate of TH was significantly lower in BP-PtCr-EES group than DP-CoCr-EES group (25%, n=6, vs 75%, n=18, p=0.03). There were no clinical events such as stent thrombosis or restenosis during the observation period in both stent groups. Conclusion Superior neointimal coverage and less YPG or TH were observed by CAS in the BP-PtCr-EES group at 1 year after stenting. Clinical significance was still unknown because of no clinical events in both groups. Prospective and large populations studies may be required. Funding Acknowledgement Type of funding source: None

scholarly journals Mobilization of Progenitor Cells and Vessel Healing After Implantation of Synergytm in Acute Coronary Syndrome

2021 ◽  
Author(s):  
Masashi Sakuma ◽  
Setsu Nishino ◽  
Takahisa Nasuno ◽  
Michiaki Tokura ◽  
Ryoichi Sohma ◽  
...  
Keyword(s):  
Optical Coherence Tomography ◽  
Acute Coronary Syndrome ◽  
Progenitor Cells ◽  
Stent Implantation ◽  
Healing Process ◽  
Coronary Syndrome ◽  
Neointimal Thickness ◽  
Coronary Stent Implantation ◽  
Coronary Angioscopy ◽  
Neointimal Coverage

Abstract This study was aimed to compare the vascular healing process of a SYNERGYTM stent with that of a PROMUS PREMIERTM stent in patients with acute coronary syndrome (ACS).　In 71 patients with ACS, undergoing coronary stent implantation using the SYNERGYTM stent (n=52) or PROMUS PREMIERTM stent (n=19), we measured circulating CD34+/CD133+/CD45null cells and CD34+/KDR+ cells and observed vascular healing at the stented sites using optical coherence tomography (OCT) and coronary angioscopy. On the day 7, circulating CD34+/CD133+/CD45null cells increased in SYNERGY group (P<0.0001), while it did not change in PROMUS group. The CD34+/KDR+ cells also increased in SYNERGY group (P<0.0001) but less significantly in the PROMUS group (P<0.05). The OCT-based neointimal thickness (P<0.0005) and neointimal coverage rate (P<0.05) at 12 months were greater in SYNERGY group, compared with PROMUS group. The coronary angioscopy-based neointimal coverage grade at 12 months was also greater in SYNERGY group (P<0.001). In overall patients, the change in CD34+/KDR+ cells on the day 7 correlated with the OCT-based neointimal thickness at 12 months (R=0.288, P<0.05).　SYNERGYTM stent seems to have potential advantages over PROMUS PREMIERTM stent for ACS patients in terms of vascular healing process at the stented sites.

Sign in / Sign up

Export Citation Format

Share Document